<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00907933</url>
  </required_header>
  <id_info>
    <org_study_id>111610</org_study_id>
    <nct_id>NCT00907933</nct_id>
  </id_info>
  <brief_title>Intranasal SB-705498 in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study in Healthy Volunteers to Examine the Safety, Tolerability and Pharmacokinetics of a) Single, Ascending and b) Twice-daily Repeat Doses of Intranasal SB-705498</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a First Time in Human (FTIH) study to investigate the safety, tolerability and&#xD;
      pharmacokinetics (PK) of a) single, escalating and b) twice-daily 14 days repeat doses of&#xD;
      intranasal SB-705498 in healthy volunteers (HVT). The safety and tolerability of single&#xD;
      intranasal 498 dosing will be assessed and established before initiating the evaluation of&#xD;
      repeat intranasal 498 dosing.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 10, 2008</start_date>
  <completion_date type="Actual">February 11, 2009</completion_date>
  <primary_completion_date type="Actual">February 11, 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability (Electrocardiogram, vital signs, lab tests, AEs and nasal tolerability</measure>
    <time_frame>Various</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1: Single dose derived pharmacokinetics (Cmax, tmax, AUC(0-4) and AUC(o-infinity); Part 2: Repeat dose derived pharmacokinetics (Cmax, tmax, AUC(0-4) and AUC(o-infinity)</measure>
    <time_frame>Part 1: Various timepoints through the day; Part 2: Various timepoints over 14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Rhinitis</condition>
  <arm_group>
    <arm_group_label>Part 1 - Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HVTs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 - Arm 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>HVTs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 - Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HVTs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 - Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HVTs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 - Arm 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HVTs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 - Arm 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HVTs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 - Arm 6</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>HVTs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 - Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HVTs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 - Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HVTs</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB-705498</intervention_name>
    <description>0.5mg intranasal SB-705498</description>
    <arm_group_label>Part 1 - Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB-705498</intervention_name>
    <description>1.5mg intranasal SB-705498</description>
    <arm_group_label>Part 1 - Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB-705498</intervention_name>
    <description>3mg intranasal SB-705498</description>
    <arm_group_label>Part 1 - Arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB-705498</intervention_name>
    <description>6mg intranasal SB-705498</description>
    <arm_group_label>Part 1 - Arm 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB-705498</intervention_name>
    <description>12mg intranasal SB-705498</description>
    <arm_group_label>Part 1 - Arm 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo '498</description>
    <arm_group_label>Part 1 - Arm 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB-705498</intervention_name>
    <description>6mg intranasal SB-705498 for 14 days bid</description>
    <arm_group_label>Part 2 - Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB-705498</intervention_name>
    <description>12mg intranasal SB-705498 14 days bid</description>
    <arm_group_label>Part 2 - Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Part 2 - Arm 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy, as determined by a responsible physician, based on a medical evaluation&#xD;
             including medical history, physical examination, laboratory tests and cardiac&#xD;
             monitoring.&#xD;
&#xD;
          -  Male or female between 18 and 60 years of age inclusive.&#xD;
&#xD;
          -  A female subject is eligible to participate if she is of:&#xD;
&#xD;
          -  Non-childbearing potential defined as females with documented tubal occlusion,&#xD;
             bilateral salpingectomy, bilateral oophorectomy or hysterectomy; or postmenopausal&#xD;
             defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample&#xD;
             with simultaneous FSH &gt; 40 MlU/ml and estradiol &lt; 40 pg/ml (&lt;140 pmol/L) is&#xD;
             confirmatory]. Females on hormone replacement therapy (HRT) and whose menopausal&#xD;
             status is in doubt will be required to use one of the contraception methods in the&#xD;
             protocol if they wish to continue their HRT during the study. Otherwise, they must&#xD;
             discontinue HRT to allow confirmation of post-menopausal status prior to study&#xD;
             enrolment. For most forms of HRT, at least 2-4 weeks should elapse between the&#xD;
             cessation of therapy and the blood draw; this interval depends on the type and dosage&#xD;
             of HRT. Following confirmation of their post-menopausal status, they can resume use of&#xD;
             HRT during the study without use of a contraceptive method.&#xD;
&#xD;
          -  Child-bearing potential and agrees to use one of the contraception methods listed in&#xD;
             the protocol. Female subjects willing to participate in the study must agree to use&#xD;
             contraception from the screening visit until 15 days post-last treatment&#xD;
             administration.&#xD;
&#xD;
          -  Male subjects must agree to use one of the contraception methods listed in the&#xD;
             protocol. For male subjects willing to participate in the study this criterion must be&#xD;
             followed from the time of the screening visit until 15 days post-last treatment&#xD;
             administration.&#xD;
&#xD;
          -  Non-smoker for at least 6 months with a pack history less than or equal to 5 pack&#xD;
             years (Pack years = (No. of cigarettes smoked/day/20) x No. of years smoked).&#xD;
&#xD;
          -  Body weight greater than or equal to 50 kg and body mass index (BMI) within the range&#xD;
             19 - 29.9 kg/m2 (inclusive).&#xD;
&#xD;
          -  Normal assessment of vital signs and 12-lead ECG at screening. A subject may be&#xD;
             included in the study if any abnormality is deemed not clinically significant by the&#xD;
             Investigator.&#xD;
&#xD;
          -  Capable of giving written informed consent, which includes compliance with the&#xD;
             requirements and restrictions listed in the consent form.&#xD;
&#xD;
          -  Available to complete all the required study measurements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Past medical history of rhinitis, including allergic, non-allergic rhinitis and&#xD;
             rhinosinusitis. Subjects with recent upper respiratory tract infections (URTIs) will&#xD;
             be allowed in the study only if their nasal symptoms have been completely resolved for&#xD;
             more than 3 weeks prior to screening.&#xD;
&#xD;
          -  Nasal conditions likely to affect the outcome of the study, i.e. nasal septal&#xD;
             perforation, nasal polyps, other nasal malformations.&#xD;
&#xD;
          -  History of frequent nosebleeds.&#xD;
&#xD;
          -  A history of gastro-intestinal, hepatic, renal or other condition known to interfere&#xD;
             with the absorption, distribution, metabolism or excretion of drugs.&#xD;
&#xD;
          -  History of regular alcohol consumption within 6 months of the study defined as: an&#xD;
             average weekly intake of greater than 21 units or an average daily intake of greater&#xD;
             than 3 units (males), or defined as an average weekly intake of greater than 14 units&#xD;
             or an average daily intake of greater than 2 units (females). One unit is equivalent&#xD;
             to a half-pint (220mL) of beer or 1 (25ml) measure of spirits or 1 glass (125ml) of&#xD;
             wine.&#xD;
&#xD;
          -  Positive pre-study drug/alcohol/smoking screen. A minimum list of drugs that will be&#xD;
             screened for include amphetamines, barbiturates, cocaine, opiates, cannabinoids,&#xD;
             benzodiazepines and methadone.&#xD;
&#xD;
          -  Positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result&#xD;
             within 3 months of screening.&#xD;
&#xD;
          -  A positive test for human immunodeficiency virus (HIV) antibody.&#xD;
&#xD;
          -  Exposure to more than four new chemical entities within 6 months prior to the start of&#xD;
             the study.&#xD;
&#xD;
          -  Participation in a clinical trial with a new molecule entity or any other clinical&#xD;
             trial within 3 months of the start of the study.&#xD;
&#xD;
          -  Use of prescription or non-prescription drugs, as well as of vitamins, herbal and&#xD;
             dietary supplements (including St John's Wort) within 7 days prior to the first dose&#xD;
             of study medication, unless in the opinion of the Investigator and GSK Medical Monitor&#xD;
             the medication will not interfere with the study procedures or compromise subject&#xD;
             safety.&#xD;
&#xD;
          -  History of drug or other allergy that, in the opinion of the Investigator or GSK&#xD;
             Medical Monitor, contraindicates participation in this study.&#xD;
&#xD;
          -  Donation of blood or blood products in excess of 500mL within a 56 day period prior&#xD;
             the start of this study.&#xD;
&#xD;
          -  Pregnant females as determined by positive serum or urine beta-human chorionic&#xD;
             gonadatrophin (beta-hCG) test at screening or prior to dosing.&#xD;
&#xD;
          -  Lactating females.&#xD;
&#xD;
          -  Unwillingness or inability to follow the procedures outlined in the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>NW10 7EW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>April 30, 2009</study_first_submitted>
  <study_first_submitted_qc>May 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2009</study_first_posted>
  <last_update_submitted>July 10, 2017</last_update_submitted>
  <last_update_submitted_qc>July 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>111610</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111610</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111610</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111610</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111610</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111610</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111610</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

